CLL (Chronic Lymphocytic Leukemia),Leukemia 4-Year Follow-Up Data of Ibrutinib and Venetoclax Combo in CLL Patients Mar 10, 2023
CLL (Chronic Lymphocytic Leukemia),Leukemia Comparing Venetoclax and Chemoimmunotherapy for CLL: GAIA/CLL13 Phase 3 Trial Mar 10, 2023
CLL (Chronic Lymphocytic Leukemia),Leukemia CLL13/GAIA Trial: FCR/BR vs. RVE, GVE, and GIVE Treatment Outcomes Mar 10, 2023
CLL (Chronic Lymphocytic Leukemia),Leukemia Phase I/II Study on Mosunetuzumab's PD Biomarkers in NHL Patients Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Impact of ADAs on uHCC Treatment in HIMALAYA Phase 3 Study Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer HRQoL Impact of Tislelizumab vs. Sorafenib in First-line uHCC: RATIONALE-301 Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer LEAP-002 Study: Lenvatinib+Pembrolizumab vs Lenvatinib+Placebo in aHCC HRQoL Comparison Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Phase 3 Trial: Pembrolizumab vs. Placebo for Second-Line HCC Treatment in Asian Patients Mar 10, 2023
